Industry’s Vaccines Pipeline In A Changing Regulatory Landscape

More than a dozen vaccines for infectious diseases are in Phase III development across the industry, as the US regulatory environment brings increased uncertainty.

Medical Ampoule Production Line
(Shutterstock)

The appointment of vaccine skeptic Robert F. Kennedy Jr. to lead the US Department of Health & Human Services (HSS) and some of the actions he has taken in his first months have raised regulatory uncertainty for vaccines, preventative products that already have a laborious development path and take many years to develop.

There are 14 vaccines in Phase III development for infectious disease, excluding next-generation COVID-19 vaccines, according to a scan of the vaccine R&D landscape by Scrip. Almost all of them are from the world’s four leading vaccines manufacturers – GSK, Sanofi, Pfizer and Merck & Co. – though the mRNA specialist Moderna has the single highest number of vaccines in Phase III development with four.

Many of the late-stage vaccines in development are against viruses with already commercially available vaccines available like flu, pneumonia and varicella, but some could fill voids in the market, including Pfizer and Valneva’s vaccine for Lyme disease and Moderna’s vaccines for cytomegalovirus and norovirus. (See chart below.)

As the US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) heads into a meeting June 25-26, the advisory group’s new working group on Lyme disease was expected to present some initial findings on epidemiology, burden and clinical manifestations, beginning preparations for a review of the new Lyme disease vaccine. The first Phase III data from Pfizer/Valneva’s Phase III VALOR trial are expected at the end of the year.

However, Kennedy’s decision to fire all 17 of the ACIP experts two weeks before the June meeting, and the backgrounds of the replacements, have raised questions about how prepared the new advisors will be to jump in on the June agenda.

Longer-term, vaccine developers are working on a wide array of vaccines relying on various mechanisms. There are around 30 vaccines in Phase II development across the industry, including several that could be the first available vaccines for conditions, like GSK’s vaccines for salmonella and Shigella, Moderna’s vaccines for Epstein-Barr virus and Herpes simplex, and Pfizer’s vaccine for Clostridioides difficile (C. difficile).

Although Pfizer has a vaccine, PF-06425090, listed as being in Phase III for C. difficile, the Phase III CLOVER trial missed its primary endpoint in 2022. The company has pivoted to an updated formulation, which is in Phase II, and will use the data from that trial to determine the next steps for the program.

More from Anti-infective

Gilead’s Yeytuo, Lilly’s Kisunla Headline CHMP Positive Opinions

 

Yeytuo will have remaining challenges to PrEP to overcome, while Kisunla’s label reflects dosing titration data from a Phase IIIb study to mitigate ARIA-E.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Moderna’s Spikevax Wins Pediatric Approval, But With Narrower Label

 

The approval for young children, consistent with the FDA’s new COVID-19 vaccine policy, restricts Spikevax to those with conditions putting them at higher risk.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

More from Business

PTC To Challenge BioMarin In PKU With Oral Sephience

 
• By 

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.

Novo Selects Internal CEO To Recharge Growth

 

Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.

CEO Underlines AstraZeneca’s Increasingly US-Centric Growth Plans

 

Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.